CSB 2.012 HistoryHistory: Cr. Register, July, 2000, No. 535, eff. 8-1-00. CSB 2.012 NoteCSB 2.26 Addition of dihydroetorphine to schedule II. (1) Section 961.16 (2) (a) 4r., Stats., is created to read: CSB 2.012 Note4r. Dihydroetorphine.
CSB 2.012 HistoryHistory: CR 01-071: Cr. Register November 2001 No. 551, eff. 12-1-01. CSB 2.012 NoteCSB 2.28 Addition of dichloralphenazone to schedule IV. (1) Section 961.20 (2) (cs), Stats., is created to read: CSB 2.012 HistoryHistory: CR 02-025: Cr. Register October 2002 No. 562, eff. 11-1-02. CSB 2.012 NoteCSB 2.29 Transfer of buprenorphine from schedule V to schedule III. (1) Section 961.18 (5m), Stats., is created to read: CSB 2.012 NoteSection 961.18 (5m) Narcotic Drugs Not Limited by Quantity. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation: CSB 2.012 Note(a) Buprenorphine
CSB 2.012 HistoryHistory: CR 03-056: cr. Register January 2004 No. 577, eff. 2-1-04. CSB 2.012 NoteCSB 2.30 Addition of gamma-hydroxybutyric acid to schedule III. (1) Section 961.18 (3) (o), Stats., is created to read: CSB 2.012 NoteSection 961.18 (3) (o) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug and cosmetic act: CSB 2.012 Note1. Gamma-hydroxybutyric acid.
CSB 2.012 HistoryHistory: CR 03-057: cr. Register January 2004 No. 577, eff. 2-1-04. CSB 2.012 NoteCSB 2.31 Addition of 2,5 dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) to schedule I. (1) Section 961.14 (4) (wh), Stats., is created to read: CSB 2.012 NoteSection 961.14 (4) (wh) 2,5 dimethoxy-4-(n)- propylthiophenethylamine, commonly known as “2C-T-7”; CSB 2.012 HistoryHistory: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.012 NoteCSB 2.32 Addition of N- benzylpiperazine (BZP) to schedule I. (1) Section 961.14 (7) (q), Stats., is created to read: CSB 2.012 NoteSection 961.14 (7) (q) N- benzylpiperazine, commonly known as “BZP.” CSB 2.012 HistoryHistory: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.012 NoteCSB 2.33 Addition of alpha-methyltryptamine (AMT) to schedule I. (1) Section 961.14 (4) (wi), Stats., is created to read: CSB 2.012 NoteSection 961.14 (4) (wi) Alpha-methyltryptamine, commonly known as “AMT”; CSB 2.012 HistoryHistory: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.012 NoteCSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). (1) Section 961.14 (4) (wj), Stats., is created to read: CSB 2.012 NoteSection 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT”; CSB 2.012 HistoryHistory: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.012 NoteCSB 2.35 Addition of lisdexamfetamine to schedule II. (1) Section 961.16 (5) (e), Stats., is created to read: CSB 2.012 NoteSection 961.16 (5) (e) Lisdexamfetamine, commonly known as “Vyvanse TM.”